i-screen.eu

What It Is

I-SCREEN is an AI screening and progression-prediction project for age-related macular degeneration (AMD). Its core goal is to use optical coherence tomography (OCT) retinal images for intelligent analysis, enabling early AMD detection, disease profiling, and progression risk assessment. According to the page, the project launched on January 1, 2024, runs for 48 months, and has a budget of €4.7 million. It is positioned more as a medical AI R&D and real-world infrastructure initiative than as a clearly commercialized SaaS tool.

Core Capabilities and Use Cases

Its AI capabilities focus on OCT image analysis: automatically detecting AMD, monitoring progression, and supporting real-world screening through cloud technology. The project emphasizes deploying the AI platform in OCT scanning scenarios used by local eye-care professionals, optometrists, or opticians, making early screening and shared care more accessible to people over 55 at the primary-care level. For a disease like AMD, which has a high population burden and significant value in early diagnosis and treatment, this direction has clear practical relevance.

Pricing, Integration, and Privacy

The website does not disclose product pricing, free trials, purchasing methods, or payment channels; it only provides the project budget. In terms of integration, the text mentions cloud-based access and use with OCT scanners in local eye-care settings, but does not specify APIs, SDKs, PACS/EHR integration, compatible devices, or deployment requirements. On privacy, the page only states that cookies and embedded YouTube content may transmit information such as IP addresses. It does not disclose details on medical imaging data governance, patient privacy protection, or compliance certifications.

Pros, Cons, and Best Fit

The main advantage is its focus on a clearly defined, high-value medical use case. By combining OCT and AI, it may improve AMD screening coverage and support shared care between primary eye-care providers and specialist medical services. The drawbacks are also obvious: there is currently little information on model performance, clinical validation, regulatory approval, commercial availability, or after-sales support, making it difficult to directly assess real-world implementation outcomes. It is best suited for ophthalmic AI researchers, innovation teams at healthcare institutions, optical chains, and public-health screening programs to monitor.

Access from China and Alternatives

Access from China is unclear. The page includes embedded YouTube content, so video playback may be restricted in mainland China. Payment and local procurement information is not disclosed. For deployment in China, local medical device registration, cross-border data transfer rules, and medical imaging compliance requirements would typically need to be considered. Domestic fundus/OCT AI screening vendors or hospital-developed ophthalmic AI systems may be worth considering as alternatives.